Table 3 SARS-CoV-2 specific antibodies titer trend during the 6-month follow-up.
Vaccine group (booster type) | Before | Day 21 | Day 60 | Day 90 | Day 180 | P-valueb |
|---|---|---|---|---|---|---|
Anti SARS-CoV-2 spike antibody (geometric mean, 95% CI) | ||||||
BBIBP-CorV | 36.1 (25.1, 51.9) | 101.9 (70.4, 147.3) | 117.0 (81.2, 168.4) | 73.5 (42.7, 126.6) | 83.7 (46.2, 151.5) | < 0.001 |
PastoCovac-Plus | 72.3 (43.8, 119.4) | 574.2 (438.5 , 751.9) | 457.0 (325.0, 642.7) | 337.0 (219.9, 516.4) | 253.3 (144.7, 443.5) | < 0.001 |
PastoCovac | 210.7 (128.6, 345.3) | 1,475.6 (1,092.4 , 1,993.3) | 524.7 (397.9, 691.9) | 247.3 (179.4, 340.9) | 134.2 (88.1, 204.2) | < 0.001 |
P-valuea | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.012 | |
Anti SARS-CoV-2 neutralizing antibody (geometric mean, 95% CI) | ||||||
BBIBP-CorV | 14.8 (10.3, 21.1) | 25.5 (21.3, 30.5) | 23.9 (18.4, 31.1) | 24.7 (18.0, 33.8) | 31.3 (28.5, 34.2) | 0.001 |
PastoCovac-Plus | 13.4 (9.0, 20.1) | 34.6 (33.5, 35.6) | 30.4 (24.4, 37.9) | 32.7 (30.3, 35.3) | 32.3 (30.3, 34.4) | < 0.001 |
PastoCovac | 18.3 (13.3, 25.0) | 34.9 (34.4, 35.4) | 35.6 (34.9, 36.4) | 33.9 (32.9, 34.9) | 29.7 (24.3, 36.4) | < 0.001 |
P-valuea | 0.648 | < 0.001 | < 0.001 | 0.344 | 0.703 | |
Anti SARS-CoV-2 RBD antibody (geometric mean, 95% CI) | ||||||
BBIBP-CorV | 52.9 (34.7, 80.7) | 115.6 (81.4, 164.0) | 81.1 (51.3, 128.4) | 48.3 (28.5, 81.9) | 76.5 (38.9, 150.1) | < 0.001 |
PastoCovac-Plus | 75.9 (41.0, 140.4) | 1432.7 (1,029.6 , 1993.8) | 465.7 (319.4 , 679.1) | 277.2 (170.0, 452.0) | 160.8 (94.9, 272.6) | < 0.001 |
PastoCovac | 117.3 (69.9 ,196.6) | 1259.6 (962.4, 1,648.6) | 415.8 (308.3 , 560.9) | 278.6 (188.8, 411.2) | 103.5 (74.1, 144.6) | < 0.001 |
P-valuea | 0.055 | < 0.001 | < 0.001 | < 0.001 | 0.081 | |
